17 December 2025
17 December 2025
Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the lucrative obesity market.
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively.
Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.
By 2030, the company anticipates employing 1,000 people at its new campus.
Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.
Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
